Ralph Snyderman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10919978/publications.pdf

Version: 2024-02-01

137 papers	6,823 citations	47006 47 h-index	79 g-index
137 all docs	137 docs citations	137 times ranked	3341 citing authors

#	Article	IF	CITATIONS
1	An Inherited Abnormality of Neutrophil Adhesion. New England Journal of Medicine, 1980, 302, 1163-1168.	27.0	304
2	Regulation of Human Chemokine Receptors CXCR4. Journal of Biological Chemistry, 1997, 272, 28726-28731.	3.4	260
3	Chemoattractant Receptor Cross-desensitization. Journal of Biological Chemistry, 1999, 274, 6027-6030.	3.4	236
4	Potential role for a guanine nucleotide regulatory protein in chemoattractant receptor mediated polyphosphoinositide metabolism, Ca++ mobilization and cellular responses by leukocytes. Biochemical and Biophysical Research Communications, 1985, 127, 450-457.	2.1	226
5	BIOLOGICAL ACTIVITY OF COMPLEMENT IN VIVO. Journal of Experimental Medicine, 1971, 134, 1131-1143.	8.5	198
6	Model for Leukocyte Regulation by Chemoattractant Receptors: Roles of a Guanine Nucleotide Regulatory Protein and Polyphosphoinositide Metabolism. Journal of Leukocyte Biology, 1986, 40, 785-800.	3.3	176
7	Targeted Disruption of the Leukotriene B4Receptor in Mice Reveals Its Role in Inflammation and Platelet-Activating Factor–Induced Anaphylaxis. Journal of Experimental Medicine, 2000, 192, 433-438.	8.5	167
8	Polymorphonuclear Leukocyte Chemotactic Activity in Rabbit Serum and Guinea Pig Serum Treated with Immune Complexes: Evidence for C5a as the Major Chemotactic Factor. Infection and Immunity, 1970, 1, 521-525.	2.2	164
9	The oligopeptide chemotactic factor receptor on human polymorphonuclear leukocyte membranes exists in two affinity states. Biochemical and Biophysical Research Communications, 1982, 106, 442-449.	2.1	147
10	Patient engagement as a risk factor in personalized health care: a systematic review of the literature on chronic disease. Genome Medicine, 2014, 6, 16.	8.2	134
11	Differential Cross-regulation of the Human Chemokine Receptors CXCR1 and CXCR2. Journal of Biological Chemistry, 1998, 273, 23830-23836.	3.4	132
12	Immunosuppressive activity of the retroviral envelope protein P 15E and its possible relationship to neoplasia. Trends in Immunology, 1984, 5, 240-244.	7.5	130
13	Substance P primes human neutrophil activation: A mechanism for neurological regulation of inflammation. Biochemical and Biophysical Research Communications, 1989, 161, 520-524.	2.1	128
14	Integrative Medicine. Archives of Internal Medicine, 2002, 162, 395.	3.8	128
15	Role of the Cytoplasmic Tails of CXCR1 and CXCR2 in Mediating Leukocyte Migration, Activation, and Regulation. Journal of Immunology, 2003, 170, 2904-2911.	0.8	126
16	Significance of Complement to the Mechanism of Action of Endotoxin. Current Topics in Microbiology and Immunology, 1969, 50, 37-77.	1.1	117
17	Factors from Saliva and Oral Bacteria, Chemotactic for Polymorphonuclear Leukocytes: Their Possible Role in Gingival Inflammation. Journal of Periodontology, 1970, 41, 71-80.	3.4	116
18	A Chemotactic Factor for Mononuclear Leukocytes. Experimental Biology and Medicine, 1971, 138, 387-390.	2.4	104

#	Article	IF	Citations
19	Similarity between p15E of murine and feline leukaemia viruses and p21 of HTLV. Nature, 1984, 311, 515-515.	27.8	104
20	Personalized health care: From theory to practice. Biotechnology Journal, 2012, 7, 973-979.	3.5	104
21	Monocyte Responsiveness to Chemotactic Stimuli is a Property of a Subpopulation of Cells that can Respond to Multiple Chemoattractants. Journal of Clinical Investigation, 1981, 67, 60-68.	8.2	102
22	Defective Mononuclear Leukocyte Chemotaxis: A Previously Unrecognized Immune Dysfunction. Annals of Internal Medicine, 1973, 78, 509.	3.9	99
23	Immunologic Reactions and Periodontal Inflammation. Journal of Dental Research, 1970, 49, 256-261.	5.2	98
24	Prospective Medicine: The Next Health Care Transformation. Academic Medicine, 2003, 78, 1079-1084.	1.6	96
25	Regulation of Human Interleukin-8 Receptor A: Identification of a Phosphorylation Site Involved in Modulating Receptor Functions. Biochemistry, 1995, 34, 14193-14201.	2.5	95
26	Abnormalities of Chemotactic Lymphokine Synthesis and Mononuclear Leukocyte Chemotaxis in Wiskott-Aldrich Syndrome. Journal of Clinical Investigation, 1974, 54, 486-493.	8.2	95
27	Cross-desensitization of Chemoattractant Receptors Occurs at Multiple Levels. Journal of Biological Chemistry, 1995, 270, 27829-27833.	3.4	88
28	Chemoattractant Receptors Activate Distinct Pathways for Chemotaxis and Secretion. Journal of Biological Chemistry, 1999, 274, 37087-37092.	3.4	88
29	MECHANISMS OF INFLAMMATION AND LEUKOCYTE ACTIVATION. Medical Clinics of North America, 1997, 81, 1-28.	2.5	87
30	Human Giprotein \hat{l}_{\pm} -subunit: deduction of amino acid structure from a cloned cDNA. FEBS Letters, 1987, 211, 160-164.	2.8	81
31	Role of Phospholipase $\hat{Cl^2}$ 3 Phosphorylation in the Desensitization of Cellular Responses to Platelet-activating Factor. Journal of Biological Chemistry, 1997, 272, 11706-11709.	3.4	79
32	Defective Monocyte Function in Patients With Genitourinary Carcinoma 2. Journal of the National Cancer Institute, 1975, 55, 1047-1054.	6.3	76
33	A pertussis/choleratoxin-sensitive N protein may mediate chemoattractant receptor signal transduction. Biochemical and Biophysical Research Communications, 1986, 138, 887-894.	2.1	7 5
34	Multiple Signaling Pathways of Human Interleukin-8 Receptor A. Journal of Biological Chemistry, 1998, 273, 10690-10695.	3.4	71
35	Molecular cloning of a new human G protein Evidence for two Giα-like protein families. FEBS Letters, 1987, 219, 259-263.	2.8	69
36	Augmentation of human monocyte chemotactic response by levamisole. Nature, 1976, 261, 136-137.	27.8	68

#	Article	IF	CITATIONS
37	Deficiency of the fifth component of complement in human subjects. American Journal of Medicine, 1979, 67, 638-645.	1.5	67
38	Regulation of the Human Chemokine Receptor CCR1. Journal of Biological Chemistry, 2000, 275, 9201-9208.	3.4	67
39	Reaction of a Cobra Venom Factor with Guinea Pig Complement and Generation of an Activity Chemotactic for Polymorphonuclear Leukocytes. Experimental Biology and Medicine, 1969, 131, 203-207.	2.4	63
40	Transmethylation reactions regulate affinity and functional activity of chemotactic factor receptors on macrophages. Cell, 1982, 28, 107-114.	28.9	61
41	Chronic mucocutaneous candidiasis. American Journal of Medicine, 1979, 67, 948-959.	1.5	60
42	Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation. Immunology Letters, 1988, 19, 7-13.	2.5	58
43	Production of Chemotactic Factor and Lymphotoxin by Human Leukocytes Stimulated with Herpes Simplex Virus. Infection and Immunity, 1974, 10, 111-115.	2.2	57
44	Differential Regulation of Formyl Peptide and Platelet-activating Factor Receptors. Journal of Biological Chemistry, 1998, 273, 11012-11016.	3.4	55
45	Interleukin-8-mediated Heterologous Receptor Internalization Provides Resistance to HIV-1 Infectivity. Journal of Biological Chemistry, 2003, 278, 15867-15873.	3.4	52
46	Signal transduction in cells following binding of chemoattractants to membrane receptors. Virchows Archiv B, Cell Pathology Including Molecular Pathology, 1988, 55, 65-80.	0.2	52
47	Isoprenylation of the low molecular mass GTP-binding proteins rac 1 and rac 2: Possible role in membrane localization. Biochemical and Biophysical Research Communications, 1990, 171, 804-812.	2.1	50
48	Generalized Microsporum audouinii infection and depressed cellular immunity associated with a missing plasma factor required for lymphocyte blastogenesis. American Journal of Medicine, 1977, 63, 991-1000.	1.5	48
49	Chemoattractant Receptor-induced Phosphorylation of L-selectin. Journal of Biological Chemistry, 1997, 272, 13961-13965.	3.4	48
50	Prospective health care: the second transformation of medicine. Genome Biology, 2006, 7, 104.	9.6	48
51	Role for Endotoxin and Complement in Periodontal Tissue Destruction. Journal of Dental Research, 1972, 51, 356-361.	5.2	47
52	Rac1, a low-molecular-mass GTP-binding-protein with high intrinsic GTPase activity and distinct biochemical properties. FEBS Journal, 1992, 206, 537-546.	0.2	47
53	Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcare. Personalized Medicine, 2012, 9, 85-91.	1.5	45
54	ABNORMALITIES OF LEUKOCYTE CHEMOTAXIS IN HUMAN DISEASE. Annals of the New York Academy of Sciences, 1975, 256, 386-401.	3.8	44

#	Article	IF	Citations
55	Function and Regulation of Chemoattractant Receptors. Immunologic Research, 2000, 22, 271-280.	2.9	44
56	Chemotaxis of Macrophages., 1976,, 323-348.		43
57	Role of transmethylation reactions in cellular motility and phagocytosis. Molecular Immunology, 1980, 17, 209-218.	2.2	42
58	Identification of a Region at the N-Terminus of Phospholipase C-β3 That Interacts with G Protein βγ Subunitsâ€. Biochemistry, 2000, 39, 1800-1806.	2.5	42
59	Cellular serine proteinase induces chemotaxis by complement activation. Nature, 1977, 269, 521-522.	27.8	41
60	Cross-desensitization Among Receptors for Platelet Activating Factor and Peptide Chemoattractants. Journal of Biological Chemistry, 1996, 271, 28717-28724.	3.4	41
61	Personalized Health Planning. Science, 2003, 300, 549-549.	12.6	41
62	Prostaglandins and inflammation: Enhancement of monocyte chemotactic responsiveness by prostaglandin E2. Prostaglandins, 1976, 12, 415-426.	1.2	39
63	Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: Immunosuppression, immunogenicity, and relation to immunosuppressive tumor products. Cancer Immunology, Immunotherapy, 1989, 30, 113-118.	4.2	39
64	Prospective care: a personalized, preventative approach to medicine. Pharmacogenomics, 2006, 7, 5-9.	1.3	39
65	Perspective: Prospective Health Care and the Role of Academic Medicine: Lead, Follow, or Get Out of the Way. Academic Medicine, 2008, 83, 707-714.	1.6	37
66	Characterization of human chemotactic lymphokine production induced by mitogens and mixed leukocyte reactions using a new microassay. Cellular Immunology, 1977, 30, 225-235.	3.0	35
67	The Clinical Researcher—An "Emerging" Species. JAMA - Journal of the American Medical Association, 2004, 291, 882.	7.4	33
68	Depression of Murine Macrophage Accumulation by Low-Molecular-Weight Factors Derived From Spontaneous Mammary Carcinomas2. Journal of the National Cancer Institute, 1980, 65, 829-834.	6.3	32
69	Thrombin Primes Responsiveness of Selective Chemoattractant Receptors at a Site Distal to G Protein Activation. Journal of Biological Chemistry, 1996, 271, 3200-3206.	3.4	32
70	Influenza-induced depression of monocyte chemotaxis: Reversal by levamisole. Cellular Immunology, 1977, 32, 234-238.	3.0	31
71	A Synthetic Peptide Homologous to Retroviral Transmembrane Envelope Proteins Depresses Protein Kinase C Mediated Lymphocyte Proliferation and Directly Inactivated Protein Kinase C: A Potential Mechanism for Immunosuppression. Microbiology and Immunology, 1991, 35, 443-459.	1.4	31
72	Prospective medicine: the role for genomics in personalized health planning. Pharmacogenomics, 2004, 5, 1-8.	1.3	31

#	Article	IF	CITATIONS
73	Improving Health by Taking It Personally. JAMA - Journal of the American Medical Association, 2010, 303, 363.	7.4	31
74	Leukocyte Activation by Chemoattractant Receptors: Roles of a Guanine Nucleotide Regulatory Protein and Polyphosphoinositide Metabolism. Clinical Infectious Diseases, 1987, 9, S562-S569.	5.8	25
75	Histamine-Releasing Factor Generated by the Interaction of Endotoxin with Hamster Serum. Infection and Immunity, 1970, 2, 462-467.	2.2	25
76	Role of guanine nucleotide regulatory protein in polyphosphoinositide degradation and activation of phagocytic leukocytes by chemoattractants. Journal of Cellular Biochemistry, 1986, 32, 59-69.	2.6	24
77	Personalized Health Care as a Pathway for the Adoption of Genomic Medicine. Journal of Personalized Medicine, 2012, 2, 232-240.	2.5	23
78	Commentary: Personalized Health Planning and the Patient Protection and Affordable Care Act: An Opportunity for Academic Medicine to Lead Health Care Reform. Academic Medicine, 2010, 85, 1665-1668.	1.6	22
79	Regulation of inositol phospholipid and inositol phosphate metabolism in chemoattractant-activated human polymorphonuclear leukocytes. Journal of Cellular Biochemistry, 1987, 35, 345-359.	2.6	21
80	Functional high efficiency expression of cloned leucocyte chemoattractant receptor cDNAs. FEBS Letters, 1992, 297, 275-279.	2.8	21
81	Value of Personalized Medicine. JAMA - Journal of the American Medical Association, 2016, 315, 613.	7.4	21
82	Effects of tumor growth on host defenses. Cancer and Metastasis Reviews, 1986, 5, 15-27.	5.9	20
83	Proposal for a new health record to support personalized, predictive, preventative and participatory medicine. Personalized Medicine, 2008, 5, 47-54.	1.5	20
84	Pharmacologic manipulation of leukocyte chemotaxis. American Journal of Medicine, 1983, 75, 10-18.	1.5	19
85	Identification of a novel inositol bisphosphate isomer formed in chemoattractant stimulated human polymorphonuclear leukocytes. Biochemical and Biophysical Research Communications, 1987, 144, 264-270.	2.1	19
86	Transductional Mechanisms of Chemoattractant Receptors on Leukocytes., 1984, 14, 1-28.		19
87	DEFECTIVE MACROPHAGE MIGRATION PRODUCED BY NEOPLASMS: IDENTIFICATION OF AN INHIBITOR OF MACROPHAGE CHEMOTAXIS11Supported in part by National Cancer Institute Contract No. NO1 CP 33313 and National Institute of Dental Research Grant 5 RO1 DE 03738-03, 1976, , 49-65.		19
88	Differential regulation of cAMP by endogenous versus transfected fornylpeptide chemoattractant receptors: Implications for Gi-coupled receptor signaling. Biochemical and Biophysical Research Communications, 1992, 183, 1033-1039.	2.1	18
89	Integration of Personalized Health Planning and Shared Medical Appointments for Patients with Type 2 Diabetes Mellitus. Southern Medical Journal, 2018, 111, 674-682.	0.7	16
90	Mechanisms of Inflammation and Leukocyte Chemotaxis in the Rheumatic Diseases. Medical Clinics of North America, 1986, 70, 217-235.	2.5	15

#	Article	IF	CITATIONS
91	Further Characterization of a Factor From Endotoxin-Treated Serum which Releases Histamine and Heparin from Mast Cells. Infection and Immunity, 1972, 5, 909-914.	2.2	15
92	Effect of C4 Depletion on the Utilization of the Terminal Components of Guinea-pig Complement by Endotoxin. Nature: New Biology, 1971, 231, 152-154.	4.5	14
93	Immunological Mechanisms of Periodontal Tissue Destruction. Journal of the American Dental Association, 1973, 87, 1020-1026.	1.5	14
94	Disorders of Leukocyte Chemotaxis. Pediatric Clinics of North America, 1977, 24, 377-393.	1.8	14
95	Effect of Membrane Fluidizers on the Number and Affinity of Chemotactic Factor Receptors on Human Polymorphonuclear Leukocytes. Microbiology and Immunology, 1983, 27, 961-972.	1.4	13
96	Advancing human health in the decade ahead: pregnancy as a key window for discovery. American Journal of Obstetrics and Gynecology, 2020, 223, 312-321.	1.3	13
97	Regulatory Mechanisms of a Chemoattractant Receptor on Human Polymorphonuclear Leukocytes. Clinical Infectious Diseases, 1985, 7, 390-394.	5.8	12
98	Compassion and Health Care. Academic Medicine, 2019, 94, 1068-1070.	1.6	12
99	AAP Presidential Address The AAP and the transformation of medicine. Journal of Clinical Investigation, 2004, 114, 1169-1173.	8.2	12
100	Factors from Saliva and Oral Bacteria, Chemotactic for polymorphonuclear Leukocytes: Their Possible Role in Gingival Inflammation. Journal of Periodontology, 1970, 41, 71-80.	3.4	12
101	A soluble inhibitor of T lymphocyte function induced by HIV-1 infection of CD4+ T cells: Characterization of a cellular protein and its relationship to p15E. Cellular Immunology, 1990, 128, 337-352.	3.0	11
102	Guanine nucleotide regulatory proteins in receptor-mediated polyphosphoinositide hydrolysis in human leukocytes. Methods in Enzymology, 1987, 141, 261-271.	1.0	9
103	Phospholipase $C^{-\hat{1}^2}$ 2 interacts with mitogen-activated protein kinase kinase 3. Biochemical and Biophysical Research Communications, 2002, 293, 647-652.	2.1	8
104	Personalized medicine 2014: has healthcare been transformed?. Personalized Medicine, 2014, 11, 365-368.	1.5	8
105	AAP Presidential Address The AAP and the transformation of medicine. Journal of Clinical Investigation, 2004, 114, 1169-1173.	8.2	8
106	Chemoattractant Receptor Affinity Reflects Its Ability to Transduce Different Biological Responses. , 1983, 12, 323-336.		7
107	The Role of Macrophages in the Rheumatic Diseases. Clinics in Rheumatic Diseases, 1978, 4, 499-515.	1.3	7
108	Personalized Health Planning in Primary Care Settings. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 27-34.	0.6	6

#	Article	IF	Citations
109	Chemotaxis of Inflammatory Cells. Journal of Dental Research, 1971, 50, 304-308.	5.2	5
110	The Role of Genomics in Enabling Prospective Health Care., 2009,, 378-385.		5
111	Health Care Reform in the United States. JAMA - Journal of the American Medical Association, 2016, 316, 1923.	7.4	4
112	Inhibitors of Monocyte Responses to Chemotaxins are Associated with Human Neoplasms. Advances in Experimental Medicine and Biology, 1982, 155, 343-352.	1.6	4
113	Creating meaningful health care reform. Journal of Clinical Investigation, 2009, 119, 2855-2855.	8.2	4
114	Precision medicine: beyond genomics to targeted therapies. Personalized Medicine, 2016, 13, 97-100.	1.5	3
115	Personalized health care in 2013: a status report on the impact of genomics. North Carolina Medical Journal, 2013, 74, 478-84.	0.2	3
116	QUANTITATION OF THE INFLAMMATORY ACCUMULATION OF MONONUCLEAR PHAGOCYTES IN VIVO. , 1981 , , $959-968$.		2
117	Chemoattractant Receptors and Signal Transduction Processes. , 1988, , 355-379.		2
118	Personalized Medical Group Visits: A Novel Approach for the Care of Prediabetes. Diabetes Spectrum, 2022, 35, 504-511.	1.0	2
119	The Role of Genomics in Enabling Prospective Health Care. , 2010, , 201-208.		1
120	Neoplasia and Mononuclear Phagocyte Function. , 1983, , 193-216.		1
121	Quantification of Lymphokine Production in Human Disease. , 1979, , 181-208.		1
122	Regulation of Leukocyte Responses to Chemoattractants: Role of Receptors, Guanine Nucleotide Regulatory (N) Proteins and Phospholipase C., 1987,, 277-289.		1
123	PHARMACOLOGICAL MANIPULATION OF THE CHEMOTACTIC FACTOR RECEPTOR ON LEUKOCYTES. , 1983, , 211-219.		1
124	An evaluation of mHealth adoption and health self-management in emerging adulthood. AMIA Annual Symposium proceedings, 2019, 2019, 1021-1030.	0.2	1
125	Regulation of Mononuclear Leukocyte Function by Transmethylation Reactionsa. Annals of the New York Academy of Sciences, 1985, 451, 256-263.	3.8	0
126	Role of a Guanine Nucleotide Regulatory Protein in the Polyphosphoinositide Pathway of Leukocyte Activation by Chemoattractant Receptors 1., 1987,, 128-139.		0

#	Article	IF	CITATIONS
127	Component Deficiencies 5. The Fifth Component. Chemical Immunology and Allergy, 1986, 39, 271-282.	1.7	O
128	Review of the national arthritis advisory board symposium, "molecular biology: its potential for advancing rheumatology researchâ€. Arthritis and Rheumatism, 1987, 30, 1191-1194.	6.7	0
129	[24] Chemoattractant-induced membrane phenomena of phagocytes. Methods in Enzymology, 1988, 162, 271-279.	1.0	0
130	More About Prospective Health Care. Academic Medicine, 2009, 84, 541.	1.6	0
131	In Reply to Goetz. Academic Medicine, 2020, 95, 972-973.	1.6	0
132	Clinical Research. Science, 2000, 287, 1927-1927.	12.6	0
133	Biologic Aspects of Leukocyte Chemotaxis. , 1977, , 159-181.		0
134	Biochemical and Biological Aspects of Leukocyte Chemotactic Factors. , 1980, , 1-19.		0
135	Mechanisms of Nonspecific Host Resistance. , 1981, , 101-114.		0
136	SPECIFIC RECEPTORS AND TRANSMETHYLATION REACTIONS ARE REQUIRED FOR LEUKOCYTE CHEMOTAXIS. , 1982, , 67-86.		0
137	The Role of the Neutrophil in the Inflammatory Response. , 1985, , 619-649.		O